Vanda's tasimelteon SET for mid-2013 US filing on PhIII sleep results in blind patients
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals gained 18.9% on the Nasdaq on 18 December after the company said its oral melatonin receptor agonist tasimelteon showed a marked improvement compared with placebo in regulating circadian rhythms for people who are blind and have trouble sleeping in normal patterns - a condition known as non-24-hour disorder - in a Phase III clinical trial.